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Abstract
Background: Although impaired health-related quality of life (HRQOL) has been reported in patients with
sarcoidosis, there is currently no sarcoidosis-specific questionnaire in Japan. The 29-item Sarcoidosis Health
Questionnaire (SHQ), originally developed in the United States, is the only sarcoidosis-specific HRQOL questionnaire
currently available. The primary aim of this study was to develop and validate a Japanese version of the SHQ.
Findings: The SHQ was translated into Japanese following the forward-backward procedure. The reliability and
validity of the Japanese version of the SHQ were examined. One hundred twenty-two Japanese patients with
biopsy-proven sarcoidosis were evaluated by the SHQ, the Medical Outcomes Study 36-item short form (SF-36), the
St. George’s Respiratory Questionnaire (SGRQ), chest radiography, an electrocardiogram, laboratory blood tests,
pulmonary function tests, an echocardiogram, and assessments of dyspnea and depressive symptoms. The SHQ
was found to have acceptable levels of internal consistency (Cronbach’s coefficient a values = 0.68 to 0.91). SHQ
scores correlated significantly with scores on the SF-36 and SGRQ. The domain or total scores on the SHQ also
significantly correlated with serum levels of the soluble interleukin-2 receptor, the percentage of the predicted
forced vital capacity, pulmonary arterial systolic pressure, dyspnea, and depressive symptoms. Also, the SHQ scores
of patients who had one or two organ systems affected by sarcoidosis were significantly different from those of
patients who had three or more organ systems involvement.
Conclusions: The Japanese version of the SHQ can be used to assess the HRQOL of patients with sarcoidosis.
Background
Sarcoidosis is a chronic and multisystem granulomatous
disease of unknown etiology that can involve almost any
organ system [1]. The assessment of overall disease burden
is often challenging in sarcoidosis because of the disease’s
various clinical manifestations. Although spirometry and
chest radiography are usually used to evaluate disease
activity, these measures fail to address extrapulmonary
lesions. As in other respiratory diseases, the patient’s
health-related quality of life (HRQOL) may be a useful
measure to assess the systemic impact of sarcoidosis [2-4],
and impaired HRQOL has been reported in sarcoidosis
[5]. Given that sarcoidosis is a chronic disease for which
there is no curative therapy yet [6], HRQOL could be the
most important outcome to measure in the management
of sarcoidosis. The incidence of sarcoidosis in Japan is
1.01 per 100,000 inhabitants, and 78.7% of patients are
symptomatic at diagnosis [7]. Additionally, sarcoidosis has
been listed as one of 130 intractable diseases by the Minis-
try of Health, Labor and Welfare in Japan. Although more
than 1,000 patients are newly diagnosed with sarcoidosis
and suffer from the disease, to date, no sarcoidosis-specific
HRQOL questionnaire has been developed that can be
used for the Japanese population.
The Sarcoidosis Health Questionnaire (SHQ), devel-
oped by Cox and coworkers in the United States (US), is
the only sarcoidosis-specificH R Q O Lq u e s t i o n n a i r e[ 8 ] .
They reported that the SHQ was more sensitive to differ-
ences in the number of involved organ systems than both
the generic Medical Outcomes Study 36-item short form
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Respiratory Questionnaire (SGRQ) [2]. We therefore
hypothesized that the SHQ would also be a useful mea-
surement of the HRQOL of patients with sarcoidosis
in Japan. Hence, we aimed to develop and validate a
Japanese version of the SHQ.
Methods
We consecutively enrolled 138 Japanese patients with
biopsy-proven sarcoidosis who presented to the Kyoto
Central Clinic between June and December 2009.
Exclusion criteria included age <18 years, presence of
an active neoplasm, and cognitive and/or reading
impairment that prevented completion of the
questionnaires.
All patients underwent chest radiography, an electro-
cardiogram, laboratory blood tests, pulmonary function
tests (PFTs), and an echocardiogram. The current extent
of organ involvement was assessed by the A Case-Control
Epidemiologic Study of Sarcoidosis (ACCESS) Organ
Involvement Index [10]. Chest radiographs were classi-
fied according to standard radiographic staging: stage 0,
normal; stage I, bilateral hilar lymphadenopathy (BHL);
stage II, BHL with pulmonary infiltrates; stage III, pul-
monary infiltrates without BHL; and stage IV, advanced
pulmonary fibrosis [11]. Serum angiotensin converting
enzyme (sACE) activity and soluble interleukin-2 recep-
tor were measured as they are known to be serum bio-
markers of sarcoidosis [12,13]. PFTs were performed by
the standardized method [14]. Left ventricular ejection
fraction (LVEF) was calculated and pulmonary arterial
systolic pressure (PASP) was estimated as described pre-
viously [15]. The Institutional Review Board of the Kyoto
Central Clinic approved this cross-sectional study, and all
patients provided written informed consent.
HRQOL was assessed by the Japanese versions of the
SF-36 [9,16] and the SGRQ [2,17]. The Japanese version of
the SHQ was developed following the forward-backward
translation procedure with independent translations and
counter-translations. The SHQ consists of three domains:
Daily Functioning (DF), Physical Functioning (PF), and
Emotional Functioning (EF). Each item was scored on a 7-
point scale, and each domain and the total score were cal-
culated by dividing the sum of the scores by the number
of items. Higher scores indicate better HRQOL on the
SHQ and SF-36, but worse HRQOL on the SGRQ. Dys-
pnea was evaluated using the Japanese version of the Med-
ical Research Council (MRC) dyspnea scale in which a
higher score indicates a worse status [18]. Depressive
symptoms were evaluated by the Japanese version of the
Center for Epidemiologic Study-Depression (CES-D, 20-
item version) Scale. In this scale, a higher score indicates
more depressed symptoms [19,20].
Data are presented as mean ± standard deviation.
Cronbach’s coefficient a was used to assess the reliability
of the questionnaire. Spearman’s rank correlation test
was used to examine the relationships between SHQ
scores and the other HRQOL measures (SF-36 and
SGRQ scores) and the clinical variables measured. The
Mann-Whitney U test was used to compare HRQOL
questionnaire scores between patients who differed in the
number of sarcoidosis-affected organ systems (organ sys-
tem involvement). Values of p < 0.05 were considered
statistically significant.
Results
Of the 138 enrolled patients, 16 were excluded because
they either did not complete the questionnaires suffi-
ciently for assessment or they had no active organ
involvement of sarcoidosis at that time. Table 1 shows
Table 1 Demographics and HRQOL/clinical findings of the study participants (n = 122)
Mean ± SD or n (%) Range
Age, years 56.8 ± 15.5 24 - 85
Female 74 (60.6%)
Duration of sarcoidosis (months) 108.9 ± 86.2 2 - 395
Number of organ systems involved 1.8 ± 0.8 1 - 5
Radiographic stage 37/32/33/15/5
(0/I/II/III/IV) (30.3%/26.2%/27.0%/12.3%/4.1%)
Blood laboratory tests
ACE, IU/L 17.2 ± 6.5 3.8 - 41.7
sIL-2R, IU/mL 639.9 ± 507.5 128 - 3772
Pulmonary function tests
FVC, %predicted 105.8 ± 18.5 44.3 - 146.4
FEV1, %predicted 105.8 ± 21.0 35.0 - 158.7
DLCO, %predicted 85.1 ± 17.2 33.7 - 133.3
Echocardiogram
LVEF, % 68.1 ± 11.4 31.8 - 79.5
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their scores on the SHQ, SF-36, SGRQ, MRC, and
CES-D.
Cronbach’s coefficient a values of the DF, PF, and EF
domains of the SHQ were 0.85, 0.68, and 0.77, respec-
tively, and the a value for the total SHQ score was 0.91.
The SHQ total score, as well as the scores for all three
domains, were essentially normally distributed (Figure 1).
The relationships between SHQ scores and the other
HRQOL measures and the clinical variables measured
are presented in Table 2. The three SHQ domain scores
and the total score all moderately to strongly correlated
with the scores on the SF-36 subscales (Spearman’sc o r -
relation coefficient, rs = 0.45 to 0.78, all p < 0.05). They
also weakly to strongly correlated with the three compo-
nent scores and the total score of the SGRQ (rs = -0.74
to -0.27, all p < 0.05). The DF, EF, and total SHQ scores
weakly correlated with sIL2-R levels (rs = -0.24 to -0.20,
all p < 0.05), while the DF, PF, and total SHQ scores
correlated with the percentage of the predicted forced
vital capacity (%FVC, one of the PFT measurements)
(rs =0 . 1 8t o0 . 2 7 ,a l lp<0 . 0 5 ) ,b u to n l yt h eP Fs c o r e
correlated with the PASP (rs = -0.38, p < 0.05). All three
domain scores and the total SHQ score moderately
Table 1 Demographics and HRQOL/clinical findings of the study participants (n = 122) (Continued)
PASP, mmHg 29.4 ± 5.9 19.0 - 57.4
SHQ
Daily Functioning [1-7] 4.7 ± 1.0 2.1 - 6.7
Physical Functioning [1-7] 5.4 ± 1.0 2.7 - 6.8
Emotional Functioning [1-7] 4.8 ± 1.0 2.2 - 6.9
Total [1-7] 4.9 ± 0.9 2.4 - 6.7
SF-36
Physical functioning [0-100] 79.2 ± 20.9 0 - 100
Role-physical [0-100] 77.1 ± 27.0 0 - 100
Bodily pain [0-100] 71.9 ± 26.7 0 - 100
General health perceptions [0-100] 50.0 ± 19.7 0 - 97
Vitality [0-100] 52.2 ± 23.1 0 - 100
Social functioning [0-100] 78.6 ± 24.1 0 - 100
Role-emotional [0-100] 77.7 ± 25.7 0 - 100
Mental health [0-100] 66.6 ± 20.5 5 - 100
SGRQ
Symptoms [0-100] 39.8 ± 20.6 0 - 86.5
Activity [0-100] 29.7 ± 24.9 0 - 92.5
Impact [0-100] 14.6 ± 14.6 0 - 57.3
Total [0-100] 23.4 ± 16.3 0 - 71.8
MRC [1-5] 1.8 ± 0.8 1 - 5
CES-D [0-60] 12.8 ± 9.3 0 - 45
The numbers in square brackets represent the theoretical score range.
On the SHQ and SF-36, higher scores indicate better status, while on the SGRQ, MRC, CES-D, lower scores indicate better status.
Abbreviations: HRQOL, health-related quality of life; SD, standard deviation; ACE, angiotensin-converting enzyme; sIL-2R, soluble interleukin-2 receptor; FVC,
forced vital capacity; FEV1, forced expiratory volume in one second; DLCO, diffusion capacity for carbon monoxide; LVEF, left ventricular ejection fraction; PASP,
pulmonary arterial systolic pressure SHQ, Sarcoidosis Health Questionnaire; SF-36, Medical Outcomes Study 36-item short form; SGRQ, St. George’s Respiratory
Questionnaire; MRC, Medical Research Council; CES-D, Center for Epidemiologic Study-Depression Scale
Figure 1 Frequency distribution histograms of the total and
domain scores on the Sarcoidosis Health Questionnaire.A
higher score indicates better health status. The theoretical score
range is from 0 to 7 on the total and all domains. Abbreviations:
SHQ, Sarcoidosis Health Questionnaire.
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-0.56 to -0.44, all p < 0.05) and the CES-D scale (rs =
-0.70 to -0.39, p < 0.05).
Patients who had involvement of one or two organ
system(s) had significantly lower scores than patients
w h oh a dt h r e eo rm o r eo r g a ns y s t e m si n v o l v e di nt h e
DF domain (p = 0.01), the EF domain (p = 0.03), the
total SHQ score (p = 0.04), and in three of the eight
subscales of the SF-36 (p < 0.01 to p = 0.04) (Table 3).
T h eS G R Qs c o r e sw e r en o ts i g n i f i c a n t l yd i f f e r e n t
between the two groups.
Discussion
In this report, we have demonstrated the reliability of
a Japanese version of the SHQ and validated it by
examining the correlations between SHQ scores and 1)
scores on other HRQOL questionnaires and 2) clinical
variables in Japanese patients with sarcoidosis.
The reliability of the translated SHQ was assessed for
internal consistency. The Cronbach’s a values for all
three domains and the total SHQ were above the 0.60
required to support construct validity [21], indicating an
acceptable level of internal consistency.
The correlations between SHQ scores and SF-36 and
SGRQ scores were weakly to strongly significant (|rs|=
0.27 to 0.75). These findings indicate that while the
translated SHQ evaluated the HRQOL of Japanese
patients with sarcoidosis, it did not necessarily measure
the same aspects as the other HRQOL questionnaires.
The SHQ scores were weakly but significantly associated
with a serum biomarker (sIL-2R), pulmonary function,
and the echocardiographic index. These correlations
indicate that the SHQ can evaluate the effects of multi-
ple pathophysiological processes in sarcoidosis that
involve several organ systems. Furthermore, the SHQ
scores more highly correlated with patient-reported out-
comes such as dyspnea (MRC) and depressive symptoms
(CES-D) than with physiological measurements. These
Table 2 Spearman’s rank correlation coefficients between
SHQ scores and other HRQOL measures and clinical
variables
SHQ-
DF
SHQ-
PF
SHQ-
EF
SHQ-
Total
SF-36
Physical functioning 0.54 0.66 0.49 0.60
Role-physical 0.70 0.60 0.66 0.74
Bodily pain 0.68 0.68 0.53 0.68
General health
perceptions
0.78 0.52 0.66 0.74
Vitality 0.77 0.54 0.70 0.77
Social functioning 0.75 0.49 0.74 0.77
Role-emotional 0.69 0.51 0.69 0.71
Mental health 0.69 0.45 0.71 0.71
SGRQ
Symptoms -0.30 -0.48 -0.27 -0.35
Activity -0.53 -0.71 -0.49 -0.59
Impact -0.49 -0.60 -0.45 -0.53
Total -0.55 -0.74 -0.51 -0.61
Radiographic stage - - - -
ACE - - - -
sIL2-R -0.24 - -0.20 -0.22
%FVC 0.18 0.27 - 0.18
%FEV1 --- -
%DLCO - - - -
LVEF - - - -
PASP - -0.38 - -
MRC -0.44 -0.56 -0.46 -0.50
CES-D -0.65 -0.39 -0.70 -0.68
Missing data (-) indicate that the relationships were not statistically significant.
Abbreviations: HRQOL, health-related quality of life; DF, Daily Functioning; PF,
Physical Functioning; EF, Emotional Functioning; SHQ, Sarcoidosis Health
Questionnaire; SF-36, Medical Outcomes Study 36-item short form; SGRQ, St.
George’s Respiratory Questionnaire; ACE, angiotensin-converting enzyme; sIL-
2R, soluble interleukin-2 receptor; FVC, forced vital capacity; FEV1, forced
expiratory volume in one second; DLCO, diffusion capacity for carbon
monoxide; LVEF, left ventricular ejection fraction; PASP, pulmonary arterial
systolic pressure; MRC, Medical Research Council; CES-D, Center for
Epidemiologic Study-Depression Scale
Table 3 Relationships between different HRQOL
measures and the organ system involvement of
sarcoidosis
One or two
organs
Three or more
organs
p
HRQOL measurements (n = 102) (n = 20)
SHQ
Daily Functioning 4.8 ± 1.0 4.2 ± 0.9 0.01
Physical Functioning 5.3 ± 0.9 5.3 ± 1.1 0.94
Emotional
Functioning
4.9 ± 1.0 4.4 ± 0.7 0.03
Total 4.9 ± 0.9 4.5 ± 0.8 0.04
SF-36
Physical functioning 81.0 ± 18.5 69.8 ± 29.4 0.08
Role-physical 79.8 ± 25.5 63.4 ± 30.7 0.02
Bodily pain 73.8 ± 25.3 62.0 ± 31.9 0.11
General health
perceptions
51.5 ± 20.2 42.3 ± 15.5 0.04
Vitality 53.4 ± 23.1 45.6 ± 22.3 0.18
Social functioning 81.0 ± 21.2 61.9 ± 31.0 <0.01
Role-emotional 79.8 ± 23.3 67.1 ± 34.1 0.17
Mental health 67.9 ± 20.4 59.5 ± 20.2 0.10
SGRQ
Symptoms 39.6 ± 21.1 41.2 ± 18.7 0.79
Activity 29.1 ± 24.9 32.6 ± 25.1 0.53
Impact 14.2 ± 14.3 17.0 ± 16.3 0.45
Total 22.9 ± 16.3 25.8 ± 16.6 0.44
All data represent mean ± SD.
Abbreviations: HRQOL, health-related quality of life; SHQ, Sarcoidosis Health
Questionnaire; SF-36, Medical Outcomes Study 36-item short form; SGRQ, St.
George’s Respiratory Questionnaire
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other diseases [17,22,23]. In all, these findings indicate
that the SHQ could be an effective assessment for a
wide range of the manifestations of the disease, includ-
ing both functional and psychological.
The validity of the SHQ was also shown by comparing
the scores between patients who differed in the extent
of organ system involvement. The SHQ scores were sig-
nificantly different between patients with one or two
organ system involvement and those with three or
more. Furthermore, compared with the SF-36 and the
SGRQ, the SHQ was better able to distinguish the
HRQOL between these two groups.
The clinical manifestations of sarcoidosis may differ
between different ethnic groups. Compared to Western
countries, sarcoidosis in Japan is less severe, but has a
higher likelihood of ocular and cardiac involvement
[7,24,25]. Thus, HRQOL and its relationship with various
clinical features may be different in the different popula-
tions. This topic should be explored in the future. Further-
more, one limitation of the study was that the
responsiveness of the SHQ over time was not examined,
because we did not target those who were newly diagnosed
or needed to start treatment as subjects for this study.
Conclusions
We have demonstrated the reliability and validity of a
Japanese version of the SHQ. The SHQ can evaluate the
HRQOL of Japanese patients with sarcoidosis, and when
added to routine radiological, serological and physiologi-
cal evaluations of the disease, can provide valuable addi-
tional information. As the SHQ is a disease-specific
questionnaire, it can evaluate what the generic SF-36
and respiratory-specific SGRQ do not evaluate.
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